• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $GEHC alert in real time by email

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.

    Logo for PharmaLogic Holdings Corporation.

    Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across global markets. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus (NASDAQ:LNTH), GE HealthCare (NASDAQ:GEHC) and Ipsen (EURONEXT: IPN).

    Steve Chilinski, who has led the company through 13 years of exceptional growth, retired as Chief Executive Officer on June 1, 2025, and will assume the role of Executive Chairman of the Board.

    "I'm grateful to Steve and the Board for their trust and their confidence in PharmaLogic's future," said Etienne Montagut. "The company has experienced great success, and I'm very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies."

    About PharmaLogic Holdings Corp.

    PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards.

    Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic across more than 30 countries.

    PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-announces-appointment-of-etienne-montagut-as-president-and-chief-executive-officer-302470235.html

    SOURCE PharmaLogic Holdings Corp

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GEHC
    $LNTH

    CompanyDatePrice TargetRatingAnalyst
    GE HealthCare Technologies Inc.
    $GEHC
    5/5/2025$73.00Sell → Neutral
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    Lantheus Holdings Inc.
    $LNTH
    12/18/2024$143.00Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    GE HealthCare Technologies Inc.
    $GEHC
    9/9/2024$90.00Neutral
    JP Morgan
    Lantheus Holdings Inc.
    $LNTH
    9/3/2024$175.00Buy
    Redburn Atlantic
    More analyst ratings

    $GEHC
    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GE HealthCare upgraded by UBS with a new price target

      UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

      5/5/25 8:34:55 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Goldman with a new price target

      Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

      3/11/25 7:35:30 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Jefferies with a new price target

      Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

      1/8/25 7:50:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    SEC Filings

    See more
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      6/9/25 4:07:02 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • SEC Form 144 filed by Lantheus Holdings Inc.

      144 - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/9/25 10:06:49 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

      SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/6/25 11:59:42 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Niedzwiecki Daniel sold $472,440 worth of shares (6,000 units at $78.74), decreasing direct ownership by 6% to 87,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/17/25 4:31:48 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Mchugh Julie sold $423,771 worth of shares (5,192 units at $81.62), decreasing direct ownership by 17% to 25,962 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:33:01 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CFO and Treasurer Marshall Robert J. Jr. exercised 14,773 shares at a strike of $49.93 and sold $3,301,296 worth of shares (39,773 units at $83.00), decreasing direct ownership by 22% to 88,860 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:32:44 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/2/24 6:00:38 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GE HealthCare announces cash dividend for second quarter of 2025

      The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

      7/1/25 8:34:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • FDA Approves Expanded Indications for GE HealthCare's Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer's Patients

      The FDA has approved an updated label for Vizamyl (flutemetamol F 18 injection), including quantification which enables a more continuous and objective measure of amyloid in the brain This approval also enables clinicians to use Vizamyl to monitor patient response to anti-amyloid therapies Other updates include now enabling the use of Vizamyl to predict development of dementia or other cognitive decline due to Alzheimer's disease, selecting patients who are indicated for anti-amyloid therapies, and establishing a diagnosis of Alzheimer's disease. The updated label enables enhanced decision making, and more confident diagnosis and monitoring of Alzheimer's disease, helping patients

      6/24/25 2:16:00 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025

      GE HealthCare continues to advance precision care in cardiology through innovative molecular imaging solutions to help support early diagnosis, tailored treatments, and improved patient outcomes. GE HealthCare's commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. As cardiovascular disease (CVD) continues to rise globally,i the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies – including positron emission tomography-computed tomography (

      6/23/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

      GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

      4/9/25 9:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

      BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

      1/30/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Financials

    Live finance-specific insights

    See more
    • GE HealthCare announces cash dividend for second quarter of 2025

      The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

      7/1/25 8:34:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

      Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year

      5/7/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • GE HealthCare reports first quarter 2025 financial results

      Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He

      4/30/25 6:20:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 8:21:14 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

      SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 3:29:28 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      11/12/24 12:53:28 PM ET
      $GEHC
      Medical Electronics
      Health Care